Figure 2 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

Key Points

• Findings indicate that drug interaction can significantly influence outcomes in immunotherapy for solid tumors.
• Multivariate analysis explored overall survival and progression-free survival across different treatment regimens.
• The phase I unit approach offers valuable insights into treatment optimization, paving the way for advanced trials.
• Further understanding of drug interactions may enhance treatment protocols in managing solid tumors.